Paeds Vivas · endocrinology-diabetes-and-growth
Type 1 diabetes: insulin therapy, technology and ambulatory care — branching viva
Branching viva from the principle that insulin is never stopped, through the sick-day child whose insulin was omitted, the pump-treated child with ketones and a normal-looking site, the hybrid closed-loop child with post-breakfast highs, and the adolescent with loss of hypoglycaemia awareness, to the targets, the transition plan, and the equity of technology access.
On this page & tools
Target exams
Branch 1 — Opening: the principle that governs everything
Examiner: "A nine-year-old with type 1 diabetes developed ketoacidosis during a viral illness because her parents stopped her insulin. State the single principle that was broken, and explain the rationale." [2]
Expected: Insulin is never stopped during an intercurrent illness. Fever, infection and the stress response raise insulin needs, so the dose is usually increased; withholding insulin is the commonest precipitant of sick-day ketoacidosis. [2]
Branch probes (examiner selects based on the answer): [2]
- If the candidate states the principle well, outline the sick-day routine the family should have followed: check glucose every 2–4 hours; check blood ketones at every glucose check; hydrate with small frequent carbohydrate-containing fluids; give extra rapid-acting insulin for hyperglycaemia with ketones per the plan; never omit basal insulin. [2]
- If the candidate hesitates, state the ketone threshold and clinical signs that should have sent them to hospital before she became acidotic: blood ketones above 1.5 mmol/L and rising; vomiting preventing fluid retention; deep or rapid breathing; drowsiness; persistent hyperglycaemia above 15–20 mmol/L. [2]
You have read the opening of this viva. The complete unit — every section and its primary-source references — is part of the Paediatrics Fellowship fellowship atlas.
References5Show ledgerHide ledger
- [1]Cengiz E; Danne T; et al ISPAD Clinical Practice Consensus Guidelines 2024: Insulin and adjunctive treatments in children and adolescents with diabetes. Horm Res Paediatr, 2024.PMID 39884261
- [2]Phelan H; Hanas R; et al Sick day management in children and adolescents with diabetes. Pediatr Diabetes, 2022.PMID 36093857
- [3]Biester T; Berget C; et al ISPAD Clinical Practice Consensus Guidelines 2024: Diabetes technologies — insulin delivery. Horm Res Paediatr, 2024.PMID 39657603
- [4]Wadwa RP; Reed ZW; et al Trial of hybrid closed-loop control in young children with type 1 diabetes. N Engl J Med, 2023.PMID 36920756
- [5]de Bock M; Agwu JC; et al ISPAD Clinical Practice Consensus Guidelines 2024: Glycemic targets. Horm Res Paediatr, 2024.PMID 39701064